Artificial surfactant therapy in hyaline-membrane disease

Area of Science:

• Neonatal Medicine
• Respiratory Physiology
• Pediatric Critical Care

Background:

• Hyaline-membrane disease (HMD) is a critical respiratory condition in preterm infants.
• Severe HMD necessitates intensive respiratory support and carries significant mortality.
• Current treatments for HMD have limitations, prompting research into novel therapies.

Purpose of the Study:

• To evaluate the efficacy of artificial surfactant administered via endotracheal instillation in preterm infants with severe HMD.
• To assess the impact of artificial surfactant on respiratory parameters, physiological markers, and radiological findings.
• To determine the safety and survival rates associated with this treatment approach.

Main Methods:

• Ten preterm infants with severe HMD received artificial surfactant via endotracheal instillation.
• Key physiological parameters including oxygenation, alveolar-arterial oxygen gradients, and systemic blood pressure were monitored.
• Respiratory support requirements (inspired oxygen, peak respirator pressure) and radiological findings were assessed.
• Incidence of complications such as patent ductus arteriosus was recorded.

Main Results:

• Significant improvements in oxygenation and alveolar-arterial oxygen gradients were observed.
• Reduced requirements for inspired oxygen and peak respirator pressure were noted.
• Radiological abnormalities associated with HMD largely resolved.
• Acidosis and systemic hypotension were reversed in treated infants.
• Nine infants developed patent ductus arteriosus post-treatment, requiring further ventilation.
• Eight out of ten infants survived, including five of six with birthweights under 1500g.

Conclusions:

• Postnatal endotracheal instillation of artificial surfactant is a potentially beneficial treatment for severe hyaline-membrane disease in preterm infants.
• The treatment demonstrated positive effects on respiratory and systemic parameters, leading to improved survival rates.
• Further investigation is warranted, considering the observed incidence of patent ductus arteriosus.